Closing gaps in early-stage NSCLC with AI-enabled clinical intelligence
A deep dive into the ASCO 2026 Landmark study on improving biomarker testing and guideline-concordant care
Session highlights
Join us for a discussion on the findings of a multi-center, prospective study presented at the ASCO 2026 Annual Meeting. The study evaluated an AI-enabled clinical decision support program deployed across six geographically and socioeconomically diverse US community health systems, resulting in an absolute lift of up to +24% in biomarker testing rates. We will explore the study’s methodology, which combined education, real-time EHR monitoring and alerts, and longitudinal feedback dashboards to address non-adherence to biomarker testing guidelines. Panelists will discuss the study’s results and the real-world implications for clinicians, patients, and the future of AI in helping clinicians ensure patients receive guideline-concordant care.
The clinical challenges and importance of timely biomarker testing for patients with early-stage NSCLC.
Key results from a multi-center study, in which implementation of an AI-enabled program was associated with an absolute lift of up to +24% in biomarker testing rates.
Perspectives from clinical investigators on how an AI-powered program can be integrated into existing workflows to support guideline-concordant care.
Conference
Webinar
